Andrade, A. Q. http://orcid.org/0000-0001-6587-3169
Widagdo, I.
Lim, R.
Kelly, T.-L.
Parfitt, G.
Pratt, N.
Bilton, R. L.
Roughead, E. E.
Funding for this research was provided by:
Department of Health and Aged Care, Australian Government (Pharmacy Trial Program)
University of South Australia
Article History
Received: 7 March 2023
Accepted: 1 July 2023
First Online: 14 July 2023
Declarations
:
: RB was employed as the ReMInDAR partnership engagement and trial manager to oversee the operations management for the trial. No other conflict of interests to declare.
: Ethics approvals have been obtained from the Human Research Ethics Committee of [blinded for review] (ID: 0000036440) and [blinded for review] (ID: H0017022). The trial adopted an “opt out approach”, and all methods were carried out in accordance with relevant guidelines and regulations. This approach was requested by the participating aged care homes, as the requirement for explicit consent would compromise the necessary level of participation. The “opt out approach” was approved by both ethics committees based on low risk carried by the trial, significant public interest and provision of information to residents and opportunity to withdraw. Written informed consent was obtained separately from participants to access to their Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS) and state hospital data through the respective data custodians.
: Not applicable.